Trial · NCT04536272
Reduced Anticoagulation Targets in ECLS (RATE)
NCT04536272, Phase 3, Completed, University Medical Center Groningen
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Reduced Anticoagulation Targets in ECLS (RATE). Trials, record NCT04536272. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT04536272
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Reduced Anticoagulation Targets in ECLS (RATE)
- NCT number
- NCT04536272
- Status
- Completed
- Phases
- Phase 3
- Enrollment
- 330 participants, actual
- Lead sponsor
- University Medical Center Groningen
- Conditions
- Heart Failure, Respiratory Failure, Extracorporeal Membrane Oxygenation, Bleeding, Thrombosis
- Interventions
- Heparin, LMWH
- First posted
- 2020-09-02
- Last updated
- 2025-05-02
- Other registries' IDs
- eudract:2019-004125-24
Source ClinicalTrials.gov
Registered outcomes10
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Hemorrhagic complications | Through ECLS completion, an average of 14 days | Severe hemorrhagic complications will be registered according to the Extracorporeal Life Support Organization (ELSO) definitions for major bleeding and is defined as clinically overt bleeding with a decrease in hemoglobin of at least 1,24 mmol/L (2 g/dl)/24 hours, or a transfusion requirement of ≥ 3 EH RBC over that same time period. Bleeding that is retroperitoneal, pulmonary or involves the central nervous system, or bleeding that requires surgical intervention is also considered major bleeding. |
| Primary | Severe thromboembolic complications | Through ECLS completion, an average of 14 days | Severe thromboembolic complication defined as ischemic stroke, limb ischemia, or acute pump failure |
| Primary | Mortality | 6 months after ECLS | Mortality at 6 months |
| Secondary | Number of blood transfusions | Through ECLS completion, an average of 14 days | Number of blood transfusions during ECLS |
| Secondary | Quality of life at 6 months | 6 months after ECLS | Quality of life (HR-QoL) measured 6 months after decannulation from ECMO |
| Secondary | Exchange of the membrane oxygenator | Through ECLS completion, an average of 14 days | Number of echanges of the membrane oxygenator during ECLS |
| Secondary | Vessel thrombosis after ECLS removal | After ECLS completion, an average of 14 days | Vessel thrombosis after ECLS removal detected by echography |
| Secondary | Cost- effectiveness | 6 months after ECLS | Cost- effectiveness will be based on reduced costs of blood transfusions and interventions for bleeding (e.g. surgery, interventional radiology) as well as improved outcome. All medical cost items expected to be affected by the ECMO therapy will be measured and valued according to the Dutch standard guidelines for economic evaluations, e.g. blood transfusion, number of ECMO replacements, surgery, and hospital length of stay. |
| Secondary | Pulmonary embolism | Through ECLS completion, an average of 14 days | The occurrence of Pulmonary embolism during ECLS |
| Secondary | All thromboembolic complications combined | Through ECLS completion, an average of 14 days | The occurrence of all thromboembolic complications combined during ECLS |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers4
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT04536272
GET https://conductscience.org/api/trials/v1/NCT04536272/registered